Formation of specific AD pathology, amyloid plaques between neurons and the accumulation of intracellular neurofibrillary tangles composed of tau, begin decades prior to the clinical expression of AD, and it is therefore essential to find a biomarker for early preclinical diagnosis and treatment monitoring. The gene discussed is MAPT; the disease is Alzheimer disease.